Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
| Revenue | $1,283,000 |
| Net Income | $-300,936,000 |
| Free Cash Flow | $-343,727,000 |
| Book Value / Share | $1.96 |
| Total Liabilities | $158,410,000 |
| Total Equity | $1,966,162,000 |
| Debt / Equity | 0.00 |
| Current Ratio | 12.88 |
| Interest Coverage | N/A |
| Working Capital | $1,817,729,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | -9.41 |
| Industry P/E | N/A |
| Forward P/E | -9.41 |
| P/B | 1.44 |
| Price / Sales | 2206.93 |
| P / FCF | -8.24 |
| EV / EBITDA | -5.05 |
| Graham Number | N/A |
| DCF (placeholder) | — |
| Gross Margin | 57.29% |
| Operating Margin | -23025.64% |
| Net Margin | -23455.65% |
| ROIC | -14.94% |
| Asset Turnover | 0.00 |
| RSI (14) | 25.13 |
| SMA 50 | 1.55 |
| SMA 200 | 1.00 |
| MACD | -0.10 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman & CEO (1964) |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director (1974) |
| Ms. Yuemei Yan | Senior Vice President of Clinical Development Operations (1970) |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery (1968) |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor (1951) |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer (1960) |
| Mr. Ming Fai Chung CPA | Company Secretary (1979) |
No news available for this company.